Post by
LithLover on Apr 05, 2021 10:47am
A little bit better but not enough
Today's news helped a bit but still not enough. So Aristotle is launched with exposure to 3,000 or more patients at Care Oncology. Add in some family members and multiple tests and at 1500 per test we are looking at a $5 million opporunity here. He mentioned about 70% profit on each test so not too shabby. Co vid revenue and millions more from Aristotle. Couple that with $7 mill in the bank and more deals and better marketing coming.
But what is the plan to get it to the masses? Is this only a roll out to Care Oncology to gain data and proof of concept if you will?
Tripp says this: " The partnership also gives us the necessary infrastructure to correctly cater to employers, where we go next"
It sounded like they have to have an infrastructure or mechanism to be able to refer positive tests into Care Oncology or some cancer treatment center due to regulations.
So is this a roll out just for Care Oncology and we can roll out to the masses in say 3 months? How will large employers, health care companies etc. get employees/patients tested? That is the huge piece we are missing and why this isn't moving.
What is the plan to really roll this out?
I'll take the added revenue, the association with Care Oncology and the real world data and media that will come from it. But to really add value it's getting this out to the market and we still didnt get any information on what is next.
Comment by
Mykndrsn on Apr 05, 2021 10:50am
I've expanded this to Rebecca who seems to believe today's pr is sufficient. Clearly the market remains confused.